Peptide Cycling and Long-Term Health: What We Know

Why people cycle peptides

Cycling means using a compound for a set block of time, then stopping before the next block. Steroid users often follow a high-dose "blast" with a lower "cruise" dose, sometimes for years (see how peptide and steroid risks compare over the long term). Peptide users mostly borrow the on/off idea instead, for two separate reasons.

The first is tolerance. Many users report that growth hormone secretagogues seem to lose their effect after weeks of steady use, usually blamed on receptor desensitization at the pituitary. The second is long-term risk: the hope that a break gives blood sugar and IGF-1 time to settle back to baseline. Both ideas are plausible, but the human evidence is much thinner than forum guides suggest. For the wider picture by peptide class, see our overview of long-term peptide health effects.

What human studies show about tolerance

Only a handful of human studies have given a growth hormone secretagogue for more than a few weeks and tracked whether the response held up. They don't all point the same way.

Hexarelin: a partial fade that reversed

The clearest test is a small 1998 UK study. Twelve healthy older adults injected hexarelin under the skin twice daily for 16 weeks. Their growth hormone response, measured as area under the curve, went from 19.1 mcg/L per hour at baseline to 13.1 at week 1, 12.3 at week 4 and 10.5 at week 16. That's a drop of about 45%, not a shutdown. When the researchers gave hexarelin again four weeks after the course ended, the response was back to 19.4, no different from where it started. The authors described the attenuation as "partial and reversible."

This fits what lifters describe. In a bodybuilding forum thread, one user wrote that people desensitize to hexarelin "pretty quick, I think like 4 weeks roughly," though in the study most of the fall came in the first week. The participants were elderly, and hexarelin produces an unusually large GH release, so its pattern may not hold for milder compounds such as ipamorelin.

MK-677: effects held for two years

Ibutamoren (MK-677) is an oral ghrelin mimetic, not an injectable peptide, but it acts on the same receptor and has the longest human data. In a two-year randomized trial of 65 healthy adults aged 60 to 81, 25 mg once daily raised GH and IGF-1 into the range of healthy young adults. The authors report that the two-year analyses confirmed the one-year results, so daily dosing with no breaks didn't erase the effect. It did come with metabolic costs, covered below.

CJC-1295 with DAC: pulses preserved

A common claim, made in an earlier version of this page, is that CJC-1295 with DAC produces a constant "bleed" of growth hormone that overrides natural pulses. The human data say otherwise. In a 2006 study, healthy men aged 20 to 40 got a single injection of 60 or 90 mcg/kg. A week later, blood drawn every 20 minutes overnight showed GH pulses with unchanged frequency and size. What rose was the floor between pulses: trough GH went up about 7.5-fold, which lifted mean GH by 46% and IGF-1 by 45%.

Earlier trials from the same program found that after two or three doses given weekly or every other week, IGF-1 stayed above baseline for up to 28 days, with "evidence of a cumulative effect." The trial evidence points to build-up rather than fading, though none of these studies ran long enough to test tolerance over months. Our CJC-1295 profile covers those trials in more detail.

Ipamorelin, GHRP-2 and GHRP-6

We found no human study that tracked whether the GH response to ipamorelin, GHRP-2 or GHRP-6 fades over weeks of repeated injections. Cycling advice for these is extrapolated from hexarelin and from animal work. In one guinea pig study of GHRP-6, injections every 60 to 90 minutes gave erratic responses, spacing them three hours apart gave steadier ones, and a low continuous infusion amplified the animals' own GH rhythm instead of blunting it. Whether that carries over to people hasn't been tested.

Repair peptides: cycling without a tolerance question

No one has shown a desensitization mechanism for BPC-157 or TB-500, so in community practice their "cycle" is usually just the length of an injury block. Forum and vendor guides commonly describe four to twelve weeks, with users stopping once the problem settles.

The long-term question here is safety. A 2025 systematic review of BPC-157 included 36 studies, 35 of them preclinical. Animal studies found no organ toxicity, but "no study assessed adverse events beyond 6 weeks," and the review found no clinical safety data in humans. Since then, a two-person intravenous pilot reported no side effects or biomarker changes after infusions of 10 mg and then 20 mg on consecutive days, which says nothing about repeated courses. TB-500 has even less: as of its April 2026 update, FDA's safety-risk page says the agency has found no human exposure data for the fragment. Each back-to-back injury block adds exposure that no study has followed.

In animal studies BPC-157 also increases signaling through VEGF, the main driver of new blood vessel growth, which feeds a common worry about tumor growth. A 2025 narrative review notes that animal work found the opposite, with BPC-157 counteracting VEGF-driven tumor growth. No study has looked at this in people.

Long-term risks a break may not fix

Cycling is often presented as the safety step. The trial data point to several specific risks, and none of those studies tested whether breaks reduce them. As of October 2026, none of these compounds is an FDA-approved medicine, so no manufacturer has had to run long-term studies (more on that in our page on peptide legal status and long-term risk).

• Blood sugar. In the two-year MK-677 trial, fasting glucose rose by an average of 5 mg/dL and insulin sensitivity fell. Cortisol went up as well. The abstract doesn't report whether these changes reversed after stopping, and we found no study that tracked recovery across repeated on/off blocks.
• A heart failure signal. A Phase IIb trial of MK-677 in 123 older adults recovering from hip fracture was stopped early because of a congestive heart failure signal in a limited number of patients. How far that applies to younger, healthy users is disputed.
• Heart rate and cardiac events with CJC-1295. FDA lists increased heart rate and a systemic vasodilatory reaction among serious adverse events. At a December 2024 advisory meeting, FDA staff described an unpublished Phase 2 trial that was stopped after a participant died of a heart attack two hours after an 11th weekly dose (the physician blamed undiagnosed coronary disease), and concluded that the drug's "long-term safety profile in humans is unknown."
• IGF-1 and cancer. In a 2004 meta-analysis of 21 case-control studies, people with higher circulating IGF-1 had a modestly higher risk of prostate cancer and premenopausal breast cancer. That's a population association, not evidence about any peptide, but it's why some users try to keep IGF-1 within the normal range.
• Antibodies and impurities. FDA flags a possible immunogenicity risk for compounded CJC-1295, ipamorelin, GHRP-6, BPC-157 and TB-500, partly because of aggregation and peptide-related impurities. For CJC-1295, FDA staff added that "data for long-term repeated exposure is lacking." Gray-market vials also vary between batches, so each new cycle can mean a different impurity profile.

Common schedules and what's behind them

These are the patterns most often described in forums and vendor guides. None has been compared with another in a trial.

Forum users most often describe the no-DAC form of CJC-1295 (Mod GRF 1-29) at 100-300 mcg alongside ipamorelin at bedtime, frequently on the 5-on, 2-off pattern. The pairing is widely described as synergistic, but we found no controlled human trial of that specific combination. Reported and trial doses for each compound are on the individual profiles.

What users track during breaks

Community guides commonly suggest blood work before a secretagogue block and again a few weeks after stopping, usually IGF-1, fasting glucose and HbA1c. Those markers match the risks the trials found. What's missing is any study showing how long they take to return to baseline, so the length of a "break" in most guides is a convention, not a measured recovery time.

Users also describe using the break to judge whether the compound was doing anything, most often by noticing changes in sleep or appetite. That kind of before-and-after comparison can't separate a real effect from expectation, but for most people it's the only feedback they have.

What we still don't know

• Whether the partial tolerance seen with hexarelin also happens with ipamorelin, GHRP-2 or GHRP-6, and how quickly.
• Whether glucose, insulin sensitivity and IGF-1 fully recover after repeated on/off blocks, and how long recovery takes.
• Whether cycling lowers any long-term risk compared with continuous use. No study has compared the two strategies head-to-head.
• What repeated courses of BPC-157 or TB-500 do over years. As of October 2026, human data on BPC-157 are limited to a few small uncontrolled reports, and there are none for the TB-500 fragment.